Caresyntax, a leader in precision surgery, has raised $180m in a series C financing round to advance its precision surgery platform. The funding comprised $100m in growth debt and $80m in equity financing.
Co-founded in 2013 by Dennis Kogan and Bjoern Von Siemens to improve patient outcomes, Caresyntax’s latest funding round was spearheaded by a consortium of companies, including BIONIQ Capital, Surgical. ai, Symbiotic Capital, BlackRock Innovation Capital and MTIP AG.
The new capital infusion will help the company accelerate the growth and development of its AI-driven surgical platform and fuel its expansion.
The massive investment underscores investors’ confidence in Caresyntax’s vision and expert team amid the soaring demand for data-driven technology solutions in the field of surgery.
A New Era of Precision Surgery
Caresyntax AI platforms offer comprehensive software designed to boost surgical precision and operational efficiency while improving patient experience through safer procedures.
The platform also provides long-term clinical decision support in real-time, enhancing data collection and analysis for improved surgical outcomes based on every patient’s scenario.
Due to its high interoperability, the platform integrates seamlessly with the systems used by hospitals and healthcare providers, helping to streamline workflow and boost operational efficiency.
Caresyntax’s platform is currently used by over 3,000 surgical professionals globally in over 3000 operation facilities.
With the new financing, the company is looking to expand the adoption of its surgical software tools, accelerate the development of edge-to-cloud applications, and pursue strategic acquisitions to bolster the platform’s capabilities.
